Clinical Trials · NCT00584298

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

Name: Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Octreotide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Novartis
Enrollment: 50
Start date: Jan 2008
Locations: 7 sites, 4 countries
Primary endpoint: - 5 sensory pressure thresholds [mmHg] from ascending method of limits (AML) barostat protocol. - 16 sensory intensity ratings from the random phasic distention (RPD) barostat protocol.

View Octreotide compound reference